FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1856-1857 April 27, 2006 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: The use of aminoglycosides as powerful broad-spectrum, bactericidal, and nonallergenic antibiotics is limited by serious side effects, including irreversible hearing loss. Nevertheless, the drugs are commonly prescribed in some situations, including as part of the regimen against multidrug-resistant tuberculosis recommended by the World Health Organization.¹ The incidence of gentamicin-induced hearing loss averages 8 percent for a short course of therapy² but may be higher in developing countries, where aminoglycosides are frequently the only affordable antibiotics and are sold over the counter. No therapy presently exists to prevent ototoxicity. Animal models suggest that ototoxicity is caused by reactive . . . [Full Text of this Article]

This article has been cited by other articles:

• Hobbie, S. N., Akshay, S., Kalapala, S. K., Bruell, C. M., Shcherbakov, D., Bottger, E. C. (2008). Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc. Natl. Acad. Sci. USA 105: 20888-20893 [Abstract] [Full Text]  
• Steyger, P. S. (2008). Synergistic Ototoxicity of Noise and Chemical Ototoxins. Hearing and Hearing Disorders: Research and Diagnostics 12: 48-54 [Abstract] [Full Text]